• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model
【24h】

Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model

机译：在大鼠模型中，脂质体包裹的血红蛋白（血红蛋白囊泡）在妊娠后期不会从母亲转移到胎儿

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Aims: Liposome-encapsulated hemoglobin (hemoglobin vesicles: HbV; diameter 250 nm) is reconstructed from human hemoglobin and developed as an artificial oxygen carrier for use as a transfusion alternative. Previous studies using rodent models closely investigated the safety of daily repeated infusions (DRI) of HbV and reported that the reticuloendothelial system was physiologically capable of degrading HbV to maintain plasma clinical chemistry within normal ranges. The present study examined the effect of DRI of HbV on the pregnant rat mother and fetal development, focusing on placental transfer of HbV in pregnancy. Main methods: Pregnant rats intravenously received HbV bolus injections at 2 ml/kg/day for the last 7 consecutive days till term. The cumulative infusion volume (14 ml/kg) was equal to 25% of the whole blood volume (56 ml/kg). Key findings: Maternal DRI of HbV had no obvious side effects on the pregnant mother or on fetal development. Maternal vital signs, plasma clinical chemistry, and blood gas parameters were overall normal after DRI of HbV. In addition, maternal/fetal transfer of HbV was limited to the placenta and HbV did not reach the fetus. Histopathological examination with human hemoglobin antibody detected HbV accumulation in the maternal spleen, liver, kidney, and placenta, but not in the fetuses. These results were also confirmed by a pharmacokinetic study using 125I-labeled HbV. Significance: This safety study of HbV use in the pregnant mother and fetus will contribute to a possible application of HbV as a potential treatment for fetal hypoxia by supplying oxygen through the placenta.
机译：目的：脂质体包裹的血红蛋白（血红蛋白囊泡：HbV;直径250 nm）是从人血红蛋白中重建而来的，并发展成为一种人造氧气载体，可以用作输血替代品。先前使用啮齿动物模型进行的研究密切研究了HbV的每日重复输注（DRI）的安全性，并报告说网状内皮系统在生理上能够降解HbV，以将血浆临床化学维持在正常范围内。本研究检查了HbV的DRI对妊娠大鼠母亲和胎儿发育的影响，重点是妊娠时HbV的胎盘转移。主要方法：妊娠大鼠连续第7天静脉输注HbV快速推注，直至足月。累计输液量（14 ml / kg）等于全血量（56 ml / kg）的25％。主要发现：孕妇的HbV DRI对孕妇或胎儿发育没有明显的副作用。 HbV DRI后，孕妇生命体征，血浆临床化学和血气参数总体正常。此外，HbV的母体/胎儿转移仅限于胎盘，而HbV尚未到达胎儿。人血红蛋白抗体的组织病理学检查发现母体脾脏，肝脏，肾脏和胎盘中有HbV蓄积，但胎儿中没有。这些结果也通过使用125 I标记的HbV的药代动力学研究得到证实。意义：这项在孕妇和胎儿中使用HbV的安全性研究将有助于通过胎盘供氧，将HbV用作潜在的治疗胎儿缺氧的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号